RT Journal Article
SR Electronic
T1 Predicting Eating Disorder and Anxiety Symptoms Using Anorexia Nervosa and Obsessive-Compulsive Disorder Polygenic Scores
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20142844
DO 10.1101/2020.07.02.20142844
A1 Yilmaz, Zeynep
A1 Schaumberg, Katherine
A1 Halvorsen, Matt
A1 Goodman, Erica L.
A1 Brosof, Leigh C.
A1 Crowley, James J.
A1 ,
A1 ,
A1 ,
A1 Mathews, Carol A.
A1 Mattheisen, Manuel
A1 Breen, Gerome
A1 Bulik, Cynthia M.
A1 Micali, Nadia
A1 Zerwas, Stephanie C.
YR 2020
UL http://medrxiv.org/content/early/2020/07/03/2020.07.02.20142844.abstract
AB Clinical, epidemiological, and genetic findings support an overlap between eating disorders, obsessive-compulsive disorder (OCD), and anxiety symptoms. However, little research has examined the role of genetic factors in the expression of eating disorders and OCD/anxiety phenotypes. We examined whether the anorexia nervosa (AN), OCD, or AN/OCD transdiagnostic polygenic scores (PGS) predict eating disorders, OCD, and anxiety symptoms in a large population-based developmental cohort. Using summary statistics files from the Psychiatric Genomics Consortium Freeze 2 AN and Freeze 1 OCD GWAS, we first conducted an AN/OCD transdiagnostic GWAS meta-analysis and then calculated PGS for AN, OCD, and AN/OCD in participants from the Avon Longitudinal Study of Parents and Children with available genetic and phenotype data on eating disorder, OCD, and anxiety diagnoses and symptoms (sample size 3,212–5,369 per phenotype). We observed sex differences in the PGS prediction of eating disorder, OCD, and anxiety-related phenotypes, with AN genetic risk manifesting at an earlier age and playing a more prominent role in eating disorder phenotypes in boys than in girls. Compulsive exercise was the only phenotype predicted by all three PGS (e.g.,PAN(boys) = 0.0141 at age 14; POCD(girls) = 0.0070 at age 16; PAN/OCD(all) = 0.0297 at age 14). Our results suggest that earlier detection of eating disorder, OCD, and anxiety-related symptoms could be made possible by including measurement of genetic risk for these psychiatric conditions while being mindful of sex differences.Competing Interest StatementThe authors report the following potential competing interests. GB received grant funding and consultancy fees in preclinical genetics from Eli Lilly, consultancy fees from Otsuka, and has received honoraria from Illumina. CMB served on Shire Scientific Advisory Boards, is a consultant for Idorsia, and receives author royalties from Pearson. All other authors have no conflicts of interest, relevant to the contents of this paper, to disclose.Funding StatementThis research was specifically funded by NIH 5R01MH073842 and R21MH109917. ZY is funded by the National Institute of Mental Health (K01MH109782; R01MH105500) and a Brain and Behavior Research Foundation NARSAD Young Investigator Award (grant # 28799). KS is supported by NIH K01MH123914 and NIH L30MH120619. SCZ is supported by NIH K01MH100435. CMB acknowledges funding from the National Institute of Mental Health (R01MH120170; R01MH119084; R21MH115397; U01 MH109528), the Swedish Research Council (VR Dnr: 538-2013-8864), and the Klarman Family Foundation. NM acknowledges grant funding from the Medical Research Council (MR/R004803/1), NIH (R01MH108595; R21MH115397), the Swiss National Fund (320030_182484), and a Brain and Behavior Research Foundation Independent Investigator Award (grant #24608). JJC acknowledges grant funding from NIH (R01MH105500; R01MH110427). The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and they will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is available on the ALSPAC website.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the ALSPAC Ethics and Law Committee. As the study comprises secondary data analysis, it was deemed to be exempt by the University of North Carolina at Chapel Hill Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers can apply to the Avon Longitudinal Study of Parents and Children (ALSPAC) for data access.